Evaluation of an 211At-labeled RGD peptide in an orthotopic glioblastoma model by targeted alpha therapy
Echigo H., Munekane M., Fuchigami T., Mishiro K., Washiyama K., Hinoi E., Takahashi K., Wakabayashi H., Kinuya S., Ogawa K.
Nuc. Med. Biol. 150-151:109572. 2025.
Integrated Spatial and Single-Cell Transcriptomics Reveals Poor Prognostic Ligand–Receptor Pairs in Glioblastoma
Yoshimoto M., Sugihara K., Tokumura K., Tsuji S., and Hinoi E#.
Cells 14(19):1540. 2025.
Potential Prognostic Markers for Glioblastoma Associated with the Glioma Immune Microenvironment
Tokumura K., Hinoi E#.
Biol. Pharm. Bull. 48(9):1319-1324. 2025.
Pharmacological inhibition of Na+/Ca2+ exchanger alleviates colitis via modulation of macrophage activity in multiple species
Nishiyama K., Hinoi E., Kuwamura M., Nabetani T., Hatoya S., Furuya M., Tani H., Nishida M., Azuma Y.
Int. Immunopharmacol. 163(115254). 2025.
PDK1-dependent metabolic reprogramming regulates stemness and tumorigenicity of osteosarcoma stem cells through ATF3
Tokumura K., Fukasawa K., Ichikawa J., Sadamori K., Hiraiwa M., and Hinoi E#.
Cell Death & Disease 16 (1):574. 2025.
Synthesis and Structure–Activity Relationships of Novel Benzofuran Derivatives with Osteoblast Differentiation-Promoting Activity
Ando M., Kawai S., Morishita K., Takashima S., Otake K., Yamamoto M., Shoji Y., Hinoi E., Kitao T., Shirahase H.
Chem. Pharm. Bull. 73(1):25-38. 2025.